AlphaMadera's AlphaVal page computes Astria Therapeutics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ATXS as undervalued, fairly valued, or overvalued.

What is Astria Therapeutics, Inc.'s fair value?

Fair value for ATXS is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ATXS?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ATXS's most recent reported fundamentals.

ATXS - Astria Therapeutics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $19.40 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: ATXS has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.